viewZelira Therapeutics Ltd

Zelda Therapeutics attracts experienced biopharmaceutical managing director

The company is focused on developing a range of cannabinoid-based medical treatments.

three empty board room seats
Last month Zelda completed patient recruitment for its insomnia clinical trial

Zelda Therapeutics Ltd (ASX:ZLD) has appointed Dr Richard Hopkins as its managing director commencing 1 July 2018.

Hopkins is an experienced biopharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies.

Dr Stewart Washer will step back from his executive position but positively will revert to a non-executive director and remain with the company.

READ: Zelda Therapeutics advancing Australia-first insomnia trial

Zelda’s executive chairman Harry Karelis said: “We have achieved much since our inception in 2015 and have developed deep relationships across the globe and created significant value for our shareholders.

“As the company prepares for its next phase of growth we are very pleased to have been able to attract someone of the calibre of Richard to join the team in a leadership position.

“We are in very capable hands and we will be working closely together to build on our success to date.

“Furthermore, the options incentive package recognises the importance of aligning the interests of management with those of shareholders.”

During Dr Hopkins’ career he has managed and overseen several strategic alliance and licensing deals with multiple global pharmaceutical partners.

He holds a PhD in molecular biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications.

Most recently, he was the CEO of biotech PharmAust Ltd (ASX:PAA) and he currently serves as chair of the Western Australian Ausbiotech Committee.

Quick facts: Zelira Therapeutics Ltd

Price: 0.08 AUD

Market: ASX
Market Cap: $94.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...


Zelira Therapeutics with Proactive at ASX Small and Mid-Cap Conference

Zelira Therapeutics Ltd (ASX:ZLD) managing director Richard Hopkins speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.  The medicinal cannabis company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing...

on 10/9/20

2 min read